Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kaushlendra Tripathi has a total of 108 co-authors. Here are the top co-authors by number of shared publications:

  • Komaraiah Palle

    Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, 1660 Springhill Avenue, Mobile, AL 36604, USA

    8 shared publications
  • Komaraiah Palle

    University of South Alabama Mitchell Cancer Institute, Mobile, AL

    6 shared publications
  • Rodney P. Rocconi

    University of South Alabama Mitchell Cancer Institute, Mobile, AL

    5 shared publications
  • Chinnadurai Mani

    Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama

    4 shared publications
  • David W. Clark

    Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama

    4 shared publications
  • Jennifer Scalici

    Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, 1660 Springhill Avenue, Mobile, AL 36604, USA

    4 shared publications

Latest Publications

  • Open Access

    Supplementary Data from ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer

    by Lora Stojanovic, Rachel Abbotts, Kaushelendra Tripathi, Collin M. Coon, Saranya Rajendran, Elnaz Abbasi Farid, Galen Hostetter, Joseph W. Guarnieri, Douglas C. Wallace, Sheng Liu, et al.

  • Open Access

    QuadCleave: Enzymatic cleavage and analysis of DNA G-quadruplexes

    by Rachael Baker, Alaina Hrysikos, Olivia Lewis, Randi Dias, Emma Younger, Tarah Anasseri, Diti Patel, Samuel Leiszler, Christopher Syed, Krishna Patel, et al.

    Prediction of G-quadruplexes (G4), noncanonical DNA secondary structures containing guanine tetrads, can have profound relevance across cancer, neurodegenerative and other genetic diseases, but require experimental validation by instrument intensive methods including CD spectroscopy, fluorescence, NMR, or crystallography. We report a novel, inexpensive, efficient and scalable 2-enzyme system for confirmation of G4 formation and copy number repeat count. First, QuadCleave, in which Mismatch Endonuclease I was used to repeatably, site-specifically and selectively cleave oligodeoxynucleotides containing exclusively G4-forming sequences. Second, HaeIII enzyme identified G4-forming sequences that can also generate GG/CC base pairs, and a sequence’s cleavage by both established it in C9ORF72, the most mutated gene in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These findings establish ubiquitously accessible experimental validation of G4 forming sequences and their copy number repeat assessment, with specificity to C9ORF72 oligodeoxynucleotides whose repeat expansion has critical clinical implications in a subpopulation of ALS and FTD patients.

  • Open Access

    Supplementary Data from ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer

    by Lora Stojanovic, Rachel Abbotts, Kaushelendra Tripathi, Collin M. Coon, Saranya Rajendran, Elnaz Abbasi Farid, Galen Hostetter, Joseph W. Guarnieri, Douglas C. Wallace, Sheng Liu, et al.

  • ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer

    by Lora Stojanovic, Rachel Abbotts, Kaushelendra Tripathi, Collin M. Coon, Saranya Rajendran, Elnaz Abbasi Farid, Galen Hostetter, Joseph W. Guarnieri, Douglas C. Wallace, Sheng Liu, et al.

    DNA methyltransferase (DNMT) and PARP inhibitors induce a stimulator of IFN gene–dependent pathogen mimicry response (PMR) in ovarian and other cancers. In this study, we showed that combining DNMT and PARP inhibitors upregulates expression of the nucleic acid sensor NFX1-type zinc finger–containing 1 (ZNFX1) protein. ZNFX1 mediated the induction of PMR in mitochondria, serving as a gateway for stimulator of IFN gene–dependent IFN/inflammasome signaling. Loss of ZNFX1 in ovarian cancer cells promoted proliferation and spheroid formation in vitro and tumor growth in vivo. In patient ovarian cancer databases, expression of ZNFX1 was elevated in advanced stage disease, and ZNFX1 expression alone significantly correlated with an increase in overall survival in a phase III trial for patients with therapy-resistant ovarian cancer receiving bevacizumab in combination with chemotherapy. RNA sequencing revealed an association between inflammasome signaling through ZNFX1 and abnormal vasculogenesis. Together, this study identified that ZNFX1 is a tumor suppressor that controls PMR signaling through mitochondria and may serve as a biomarker to facilitate personalized therapy in patients with ovarian cancer. Significance: DNMT and PARP inhibitors induce a nucleic acid sensor, ZNFX1, that serves as a mitochondrial gateway to STING-dependent inflammasome signaling with tumor suppressor properties in ovarian cancer.


  • Detection and evaluation of estrogen DNA‐adducts and their carcinogenic effects in cultured human cells using biotinylated estradiol

    by Kaushlendra Tripathi, Chinnadurai Mani, Ranganatha R. Somasagara, David W. Clark, Venkateshwari Ananthapur, Kambappa Vinaya, Komaraiah Palle

    The normal female reproductive hormone estrogen has been linked with increased risk of breast and many other forms of cancer. This is largely due to metabolic conversion of estrogens into highly reactive catechol estrogen quinones which can interact with DNA and cause a variety of DNA adducts and lesions. Detection and analysis of these adducts and their associated cellular responses involve complex chemical, enzymatic, and LC-MS based methods, which are both laborious and require specialized expertise and instrumentation. Herein, we show that using a biotin-labeled estradiol allows immunodetection of estrogen-induced DNA adducts by slot blot and single-cell molecular combing and proximity ligation assays. The biotinylated and unlabeled estradiols induced similar levels of DNA single and double strand breaks as measured by comet assays. Using biotinylated estrogen, we further show that estrogens are able to activate the Fanconi anemia-BRCA tumor suppressor pathway and cause DNA strand breaks and oxidatively modified DNA bases as well as gross chromosomal aberrations. Utilization of biotin-labeled estrogens could be a powerful tool to detect estrogen adducts and associated DNA damage, and to track estrogen adduct-induced cellular responses and carcinogenic mechanisms in cultured cells. The techniques presented here allow simple and rapid detection and quantitation of estrogen adducts by slot blot as well as direct visualization on the DNA strand and could pave the way for developing new treatments to protect the genome from the effects of reactive estrogen metabolites.


  • Abstract 3734: Preclinical evaluation of Rad6 inhibition to overcome platinum resistance in ovarian cancer

    by Sebastian M. Spencer, Ranganatha R. Somasagara, Kaushlendra Tripathi, David W. Clark, Hend Kothayer, Andrew D. Westwell, Rodney P. Rocconi, Komaraiah Palle

    Ovarian cancer (OC) is the most lethal gynecological cancer in women in the United States. Advances in surgery and chemotherapy have not significantly changed the overall survival rate of OC for the last few decades, which highlights the need for new therapeutic strategies. Platinum drug resistance and refractory disease pose major challenges in treating this disease and are major factors contributing to the poor survival rate of OC patients. Although most patients initially respond to platinum based chemotherapy, about 80% of cases present with recurrent disease, develop platinum resistance, and die with the advanced disease. Considering the heterogeneity, small fractions of the cells could be inherently resistant to chemotherapy and/or dormant and exhibit stem-like cell properties, contributing to the resistant phenotype and disease recurrence. Although the Cancer stem cell (CSC) theory of therapeutic resistance proposes that the proportion of CSCs correlate to enhanced chemoresistance and early disease recurrence, the specific molecular mechanisms that regulate tumor cell behavior (stemness) and integrate signaling networks with aberrant oncogenic signaling in OC cells are not known. Our analysis of clinical samples revealed upregulation of Rad6, an E2 ubiquitin conjugating enzyme, in more than 80% of ovarian tumors compared to normal ovarian tissues. Upregulation of Rad6 also correlated well with tumor progression. Further analysis of molecular pathways in OC cells revealed a strong correlation between Rad6 upregulation and increased β-catenin and hedgehog signaling, stem cell like characteristics and platinum resistance. Downregulation of Rad6 using siRNAs or inhibition of its catalytic activity by a small molecule inhibitor, attenuated carboplatin induced monoubiquitination of its target proteins such as histone 2B, PCNA and proteins of the Fanconi anemia pathway thereby sensitizing OC cells to carboplatin. Interestingly, inhibition of Rad6 alone in OC cells induced replication stress and reduced cell survival and proliferation by arresting cells in the G2/M phase. Moreover, inhibition of Rad6 in various OC cell lines reduced expression of β-catenin, Gli1 and several OC stem cell markers. Moreover, Rad6 plays an important role in the activation of the trans-lesion synthesis (TLS) pathway by monoubiquitinating PCNA and in the activation of the Fanconi Anemia (FA) DNA repair pathway. These are critical mechanisms for cells to repair DNA crosslinks induced by platinum drugs. Together with these observations, our data suggest that inhibition of Rad6 could be a viable therapeutic target for overcoming platinum resistance and disease recurrence in ovarian cancer. Citation Format: Sebastian M. Spencer, Ranganatha R. Somasagara, Kaushlendra Tripathi, David W. Clark, Hend Kothayer, Andrew D. Westwell, Rodney P. Rocconi, Komaraiah Palle. Preclinical evaluation of Rad6 inhibition to overcome platinum resistance in ovarian cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3734.

  • Open Access

    Rad18 is required for functional interactions between FANCD2, BRCA2, and Rad51 to repair DNA topoisomerase 1-poisons induced lesions and promote fork recovery

    by Kaushlendra Tripathi, Chinnadurai Mani, David W Clark, Komaraiah Palle

    Rad18 is required for functional interactions between FANCD2, BRCA2, and Rad51 to repair DNA topoisomerase 1-poisons induced lesions and promote fork recovery


  • Rad6 upregulation promotes stem cell-like characteristics and platinum resistance in ovarian cancer

    by Ranganatha R. Somasagara, Kaushlendra Tripathi, Sebastian M. Spencer, David W. Clark, Reagan Barnett, Lavanya Bachaboina, Jennifer Scalici, Rodney P. Rocconi, Gary A. Piazza, Komaraiah Palle


  • Open Access

    Aberrant GLI1 Activation in DNA Damage Response, Carcinogenesis and Chemoresistance

    by Komaraiah Palle, Chinnadurai Mani, Kaushlendra Tripathi, Mohammad Athar

    The canonical hedgehog (HH) pathway is a multicomponent signaling cascade (HH, protein patched homolog 1 (PTCH1), smoothened (SMO)) that plays a pivotal role during embryonic development through activation of downstream effector molecules, namely glioma-associated oncogene homolog 1 (GLI1), GLI2 and GLI3. Activation of GLIs must be tightly regulated as they modulate target genes which control tissue patterning, stem cell maintenance, and differentiation during development. However, dysregulation or mutations in HH signaling leads to genomic instability (GI) and various cancers, for example, germline mutation in PTCH1 lead to Gorlin syndrome, a condition where patients develop numerous basal cell carcinomas and rarely rhabdomyosarcoma (RMS). Activating mutations in SMO have also been recognized in sporadic cases of medulloblastoma and SMO is overexpressed in many other cancers. Recently, studies in several human cancers have shown that GLI1 expression is independent from HH ligand and canonical intracellular signaling through PTCH and SMO. In fact, this aberrantly regulated GLI1 has been linked to several non-canonical oncogenic growth signals such as Kirsten rat sarcoma viral oncogene homolog (KRAS), avian myelocytomatosis virus oncogene cellular homolog (C-MYC), transforming growth factor β (TGFβ), wingless-type MMTV integration site family (WNT) and β-catenin. Recent studies from our lab and other independent studies demonstrate that aberrantly expressed GLI1 influences the integrity of several DNA damage response and repair signals, and if altered, these networks can contribute to GI and impact tumor response to chemo- and radiation therapies. Furthermore, the ineffectiveness of SMO inhibitors in clinical studies argues for the development of GLI1-specific inhibitors in order to develop effective therapeutic modalities to treat these tumors. In this review, we focus on summarizing current understanding of the molecular, biochemical and cellular basis for aberrant GLI1 expression and discuss GLI1-mediated HH signaling on DNA damage responses, carcinogenesis and chemoresistance.